Pfizer's bococizumab data in-line with PCSK9 competitors
This article was originally published in Scrip
Pfizer reported top-line results from a Phase IIb clinical trial that show the highest twice-monthly dose of bococizumab (RN316) cut bad cholesterol levels almost in half, but the company is playing catch-up with two similarly effective PCSK9 inhibitor developers.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.